(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 10.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Biocryst Pharmaceuticals's revenue in 2025 is $557,506,000.On average, 4 Wall Street analysts forecast BCRX's revenue for 2025 to be $130,088,740,073, with the lowest BCRX revenue forecast at $128,397,831,010, and the highest BCRX revenue forecast at $132,484,981,782. On average, 4 Wall Street analysts forecast BCRX's revenue for 2026 to be $141,234,885,145, with the lowest BCRX revenue forecast at $137,871,540,015, and the highest BCRX revenue forecast at $144,526,017,646.
In 2027, BCRX is forecast to generate $158,493,073,456 in revenue, with the lowest revenue forecast at $151,388,316,503 and the highest revenue forecast at $164,835,819,249.